JAZZ - Jazz's new dosing regimen of Rylaze as part of cancer chemotherapy shows promise in trial

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported data from a phase 2/3 trial of a new dosing regimen of its therapy Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn). The results — which were presented at the American Society of Clinical Oncology (ASCO) meeting — were from Part A of the study, which included three groups. The study, conducted in collaboration with the Children's Oncology Group (COG), evaluated the Monday/Wednesday/Friday (MWF) intramuscular (IM) dosing schedule for Rylaze for use as a component of a multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase. The company said ?90% of patients in group 1c receiving the IM dosing regimen of 25/25/50 mg/m2 administered MWF achieved nadir serum asparaginase activity (NSAA) levels ?0.1 IU/mL at 48 and 72 hours. The safety profile was consistent with what has been seen for other asparaginases, the company noted. Jazz added

For further details see:

Jazz's new dosing regimen of Rylaze as part of cancer chemotherapy shows promise in trial